GlassScriptPhysician profile
Dana Parrish Branchetti
NPI 1306496955
$5,414.20
in general payments reported to CMS, 2019-2025
47 companies · $1,983 in 2025
The $1,983 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.95 · 2022: $424 · 2023: $1,054 · 2024: $1,853 · 2025: $1,983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,411 · Education: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,410.92 |
| Education | $479.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $467.32 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $442.20 | 2023-2025 | Lynparza, Enhertu, Calquence |
| Pfizer INC. | $376.88 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $320.71 | 2023-2025 | Libtayo |
| Gilead Sciences, INC. | $294.95 | 2022-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $268.25 | 2023-2025 | |
| Incyte Corporation | $258.52 | 2021-2024 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $253.23 | 2023-2024 | Opdivo, Reblozyl |
| Stemline Therapeutics INC. | $211.90 | 2023-2025 | Orserdu |
| Janssen Biotech, INC. | $183.41 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Abbvie INC. | $177.41 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $172.30 | 2023-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Jazz Pharmaceuticals INC. | $162.89 | 2023-2024 | |
| Daiichi Sankyo INC. | $143.08 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $132.46 | 2022-2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $123.67 | 2023-2025 | Brukinsa |
| Amgen INC. | $123.46 | 2023 | Lumakras |
| Sobi, INC | $122.05 | 2024-2025 | |
| Lilly USA, LLC | $102.94 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Janssen Scientific Affairs, LLC | $93.71 | 2022 | |
| Genzyme Corporation | $92.53 | 2025 | |
| Puma Biotechnology, INC. | $76.65 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $74.99 | 2025 | |
| Glaxosmithkline, LLC. | $72.34 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Astellas Pharma US INC | $53.82 | 2024-2025 | Xtandi, Padcev |
| Beone Medicines USA, INC. | $51.89 | 2025 | Brukinsa |
| Myriad Genetic Laboratories, INC. | $48.53 | 2024 | Precisetumor |
| Seagen INC. | $38.42 | 2023 | Padcev, Tukysa |
| Deciphera Pharmaceuticals INC. | $38.16 | 2024-2025 | Qinlock, Romvimza |
| Eisai INC. | $37.64 | 2024-2025 | |
| Array Biopharma INC | $37.50 | 2024-2025 | Braftovi, Tukysa, Mektovi |
| Karyopharm Therapeutics INC. | $37.21 | 2024 | Xpovio |
| Exelixis INC. | $36.80 | 2025 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $35.31 | 2024 | Ultomiris |
| Taiho Oncology, INC. | $32.56 | 2025 | |
| Immunogen, INC. | $22.04 | 2023 | Elahere |
| Celgene Corporation | $21.64 | 2023 | Reblozyl |
| Foundation Medicine, INC. | $21.19 | 2023 | |
| Legend Biotech USA INC. | $20.33 | 2025 | Carvykti |
| Geron Corporation | $19.73 | 2025 | Rytelo |
| G1 Therapeutics, INC. | $18.82 | 2023 | Cosela |
| Tempus Ai, INC | $18.62 | 2024 | |
| Nuvation Bio INC. | $17.46 | 2025 | Ibtrozi |
| Caris Mpi, INC. | $15.62 | 2025 | Mi Cancer Seek |
| Coherus Oncology, INC. | $14.75 | 2024 | |
| Pharmacosmos Therapeutics INC. | $14.30 | 2024 | Cosela |
| Mirati Therapeutics, INC. | $14.01 | 2024 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Branchetti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.